Actively Recruiting
Randomized, Double-Masked, Placebo-Controlled Study Evaluating Safety and Pharmacology of ETHY-001 in Thyroid Eye Disease
Led by Ethyreal Bio, Inc. · Updated on 2026-10-26
72
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying ETHY-001 to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and people with Thyroid Eye Disease TED. This Phase 1 trial uses a randomized, double-masked, placebo-controlled design to assess the effects of single ascending doses of ETHY-001. The study aims to understand how the drug behaves in the body and its safety profile over an extended period. Participants will be assigned to receive either ETHY-001 or a placebo in multiple cohorts with increasing single doses given by subcutaneous injection. The trial includes a placebo comparator group to evaluate differences between the study drug and no active treatment. This design helps researchers observe the clinical activity and safety of ETHY-001 in a controlled setting. During the study, participants will be monitored closely for adverse events from the first day through up to 84 weeks. Assessments include monitoring safety through reported side effects and clinical evaluations. Participants must comply with protocol requirements, including medication restrictions and monitoring instructions. The long follow-up period allows detailed observation of the drugs effects and participant well-being throughout the trial.
CONDITIONS
Brief Title
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
Research Team
E
Ethyreal Bio
E
Ethyreal Bio
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here